NCT00544219COMPLETEDanonymous

Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study

Sponsor

Source record

Swiss Cancer Institute

Phase

Source record

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Indication / condition

AI-normalized

Lymphoma

Intervention

Source record

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Source & freshness

Source record

NCT ID

NCT00544219

Original source

ClinicalTrials.gov

Source last updated

May 15, 2019

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00544219

Title

Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study

Sponsor

Swiss Cancer Institute

Status

COMPLETED

Phase

Condition raw

Lymphoma

Condition normalized

Lymphoma

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Target normalized

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Interventions

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Public preview

Source record

RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00544219

Status

COMPLETED

Phase

Sponsor

Swiss Cancer Institute

Executive brief

Investment-Ready Snapshot

RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 15, 2019

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00544219

Indication

Lymphoma

Modality

monoclonal antibody

Target

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Intervention

rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.